<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:05:16Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14648" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/14648</identifier><datestamp>2026-10-18T21:14:24Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction</dc:title><dc:creator>Karabakan, Mehmet</dc:creator><dc:creator>Keskin, Ercument</dc:creator><dc:creator>Akdemir, Serkan</dc:creator><dc:creator>Bozkurt, Aliseydi</dc:creator><dc:subject>Ejaculation</dc:subject><dc:subject>Erectile dysfunction</dc:subject><dc:subject>Tadalafil</dc:subject><dc:subject>Therapeutics</dc:subject><dc:subject>Adult</dc:subject><dc:subject>Aged</dc:subject><dc:subject>Blood Glucose</dc:subject><dc:subject>Cholesterol</dc:subject><dc:subject>Drug Administration Schedule</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Lower Urinary Tract Symptoms</dc:subject><dc:subject>Male</dc:subject><dc:subject>Middle Aged</dc:subject><dc:subject>Penile Erection</dc:subject><dc:subject>Phosphodiesterase 5 Inhibitors</dc:subject><dc:subject>Premature Ejaculation</dc:subject><dc:subject>Retrospective Studies</dc:subject><dc:subject>Statistics, Nonparametric</dc:subject><dc:subject>Surveys and Questionnaires</dc:subject><dc:subject>Testosterone</dc:subject><dc:subject>Time Factors</dc:subject><dc:subject>Treatment Outcome</dc:subject><dc:subject>glucose blood level</dc:subject><dc:subject>phosphodiesterase V inhibitor</dc:subject><dc:subject>analysis</dc:subject><dc:subject>blood</dc:subject><dc:subject>drug administration</dc:subject><dc:subject>drug effects</dc:subject><dc:subject>human</dc:subject><dc:subject>nonparametric test</dc:subject><dc:description>Objective: To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods: A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire- 5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients. Results: The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p &lt; 0.01). Conclusion: A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.</dc:description><dc:publisher>Brazilian Society of Urology</dc:publisher><dc:date>2017</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/14648</dc:identifier><dc:identifier>https://doi.org/10.1590/s1677-5538.ibju.2016.0376</dc:identifier><dc:identifier>1677-5538</dc:identifier><dc:language>en</dc:language><dc:relation>International Braz J Urol</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14648</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>